Alpha-0261 / AlphaMol Science - LARVOL DELTA

An open-label, single-arm, multicenter study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of Alpha-0261 tablets in patients with moderate to severe active ulcerative colitis (UC) (ChiCTR) - P=N/A | N=10 | Not yet recruiting | Sponsor: The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university

New trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: The First Affiliated Hospital of Anhui Medical University

New P1 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis

Phase Ib, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study of Alpha-0261 Tablets to Assess Safety and Tolerability in Patients With Chronic Spontaneous Urcaria (Part 1) and Food Effect in Healthy Adults (Part 2). (clinicaltrials.gov) - P1 | N=48 | Not yet recruiting | Sponsor: AlphaMol Science Ltd. (Shanghai)

New P1 trial • Chronic Spontaneous Urticaria • Dermatology • Immunology • Urticaria

A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=55 | Completed | Sponsor: AlphaMol Science Ltd. (Shanghai) | Recruiting ➔ Completed

Trial completion

A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: AlphaMol Science Ltd. (Shanghai)

New P1 trial